To promote the development of more treatments for rare diseases, sponsors should leverage data from natural history studies when it is not possible to use data from two adequate and well-controlled ...
Merck, Lundbeck and Ionis Pharmaceuticals are seeking more details from the US Food and Drug Administration’s (FDA) draft guidance on natural history studies, including discussions of using ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results